LungLife AI, Inc. (GB:LLAI) has released an update.
LungLife AI, Inc., a company pioneering in diagnostic solutions for lung cancer, has announced Medicare’s finalized coverage for their LungLB® test, which aids in diagnosing lung cancer from indeterminate pulmonary nodules. This coverage is a significant milestone for LungLife, allowing them to receive payment for tests conducted from September 22, 2024, onwards and paving the way for broader commercialization. The company views this development as a key opportunity to make early lung cancer detection more widely available and reimbursable by Medicare.
For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.
